Myelin basic protein
- Generic Name
- Myelin basic protein
- Drug Type
- Biotech
- Unique Ingredient Identifier
- SSA5AV2ZFK
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
Phase 1
Completed
- Conditions
- Myelogenous Leukemia, Acute
- Interventions
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 122
- Registration Number
- NCT01773408
- Locations
- 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸Cancer Therapy & Research Ctr; Dept Institute for Drug Development, San Antonio, Texas, United States
🇨🇦McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath